Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 7/20 | 0.93 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.93 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.93 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.93 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.93 |
| ▸ | SRC | P12931 | 2/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.93 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.93 |
| ▸ | RNASEL | Q05823 | 4/20 | 0.90 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.86 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.86 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.86 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.86 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.82 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.82 |
| ▸ | LDHA | P00338 | 1/20 | 0.82 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.82 |
| ▸ | FBP1 | P09467 | 1/20 | 0.82 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Triphosphate SCHEMBL3459127 | 1.00 | P2RY1 (0.93) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL193645 | 1.00 | P2RY1 (0.93) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL28356 | 1.00 | P2RY1 (0.93) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL28358 | 1.00 | P2RY1 (0.93) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL1496267 | 1.00 | P2RY1 (0.93) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL28204853 | 1.00 | P2RY1 (0.93) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL23752112 | 0.99 | P2RY1 (0.91) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL4594616 | 0.99 | P2RY1 (0.91) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL27523058 | 0.99 | P2RY1 (0.91) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL3498798 | 0.99 | P2RY1 (0.91) | P2RY1P2RX1P2RX3P2RY2P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117467715-A | Process for simultaneously preparing D-glutamic acid and L-glutathione by multi-step enzyme method | 珠海瑞德林生物有限公司 | 2024-01-30 | — | — | CN | claimed |
| US-20230386615-A1 | BINDING SITE IN TYPE 1 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-30 | — | — | US | claimed |
| US-20230368862-A1 | BINDING SITE IN TYPE 2 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-16 | — | — | US | claimed |
| CN-113101908-A | Hybrid ligand hierarchical pore metal organic framework material and preparation method and application thereof | 华南理工大学 | 2021-07-13 | — | — | CN | claimed |
| CN-111041067-A | Reagent and method for detecting β -lactamase and inhibiting drug resistance of compound agent thereof | 赛莱克斯(深圳)科技有限公司 | 2020-04-21 | — | — | CN | claimed |
| CN-103609553-A | Kidney preservation liquid containing lycium barbarum polysaccharide | SICHUAN ACADEMY OF MEDICAL SCIENCES & SICHUAN PROVINCIAL PEOPLES HOSPITAL | 2014-03-05 | — | — | CN | claimed |
| US-20020168328-A1 | Cell photoprotective complex anti-pollution agent | L'OREAL (FR) | 2002-11-14 | — | — | US | claimed |
| CN-121242142-A | Feed additive for preventing and improving low-phosphorus leg disease of poultry and preparation method and application thereof | 扬州大学 | 2026-01-02 | — | — | CN | disclosed |
| CN-120754015-A | Scalp care composition and preparation method thereof | 北京圣美细胞生命科学工程研究院有限公司 | 2025-10-10 | — | — | CN | disclosed |
| EP-4570798-A1 | AROMATIC HETEROCYCLIC CYCLOHEXYL AMINOALKYL PIPERIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2025-06-18 | — | — | EP | disclosed |
| CN-118562917-A | Method for biosynthesis of guanosine diphosphate by multienzyme method | 汇海(苏州)生物技术有限公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-3925997-B1 | BIOMASS-RESOURCE-DERIVED POLYESTER AND PRODUCTION PROCESS THEREOF | MITSUBISHI CHEM CORP (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20240158785-A1 | ANTIGEN-BINDING MOLECULES, THE ANTIGEN-BINDING ACTIVITY OF WHICH VARIES ACCORDING TO THE CONCENTRATION OF COMPOUNDS, AND LIBRARIES OF SAID MOLECULES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-16 | — | — | US | disclosed |
| CN-1276246-A | Process for preparing medicines with no or low loxic by-effect on gastrointestinal system | WANG XIAO (CN) | 2000-12-13 | — | — | CN | disclosed |
| US-5695796-A | MUTANT LACTOBACILLUS LACTIC ACID BACTERIA | THE CALPIS FOOD INDUSTRY CO., LTD. (JP) | 1997-12-09 | — | — | US | disclosed |
| CN-1140709-A | Substituted N- (indole-2-carbonyl) -beta-alaninamides and derivatives as antidiabetics | PFIZER (US) | 1997-01-22 | — | — | CN | disclosed |
| US-5541111-A | Lactobacillus helveticus mutants having low increase in acidity of lactic acid during storage | THE CALPIS FOOD INDUSTRY CO., LTD. (JP) | 1996-07-30 | — | — | US | disclosed |
| EP-0652285-A2 | Lactic acid bacteria and fermented milk product | The Calpis Food Industry Co., Ltd. (JP) | 1995-05-10 | — | — | EP | disclosed |
| US-4164571-A | Medicament which antagonizes the action of gastrin and related polypeptides | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1979-08-14 | — | — | US | disclosed |
| US-4046879-A | TOPICAL | BOEHRINGER INGELHEIM GMBH (DT) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230368862-A1 | BINDING SITE IN TYPE 2 RYANODINE RECEPTOR | RYR2, RYR1, ATP2A2 | P2RY1 354/4885P2RX1 440/4885P2RX3 336/4885 |
| US-20240158785-A1 | ANTIGEN-BINDING MOLECULES, THE ANTIGEN-BINDING ACTIVITY OF WHICH VARIES ACCORDING TO THE CONCENTRATION OF COMPOUNDS, AND LIBRARIES OF SAID MOLECULES | MICA, CD69, CD74 | P2RY1 3771/4885P2RX1 2979/4885P2RX3 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.